F Stephen Hodi

List of Publications by Citations

176 papers	59,457 citations	77 h-index	188 g-index
188 ext. papers	73,016 ext. citations	13.5 avg, IF	7.24 L-index

#	Paper	IF	Citations
176	Improved survival with ipilimumab in patients with metastatic melanoma. *New England Journal of Medicine*, **2010**, 363, 711-23	59.2	10591
175	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*, **2012**, 366, 2443-54	59.2	8684
174	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *New England Journal of Medicine*, **2015**, 373, 23-34	59.2	5047
173	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* , **2014**, 515, 563-7	50.4	3354
172	Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clinical Cancer Research*, **2009**, 15, 7412-20	12.9	2380
171	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2017**, 377, 1345-1356	59.2	2030
170	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *New England Journal of Medicine*, **2015**, 372, 2006-17	59.2	2001
169	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of Clinical Oncology*, **2015**, 33, 1889-94	2.2	1425
168	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine*, **2019**, 381, 1535-1546	59.2	1260
167	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. *Lancet Oncology, The*, **2017**, 18, e143-e152	21.7	1010
166	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2004-12	2.2	859
165	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell*, **2017**, 171, 934-949.e16	36.2	831
164	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2017**, 35, 785-792	2.2	696
163	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncology, The* , **2018**, 19, 1480-1492	21.7	680
162	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1600-9	27.4	666
161	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *New England Journal of Medicine*, **2018**, 379, 722-730	59.2	659
160	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 1558-1568	21.7	627

159	RECIST 1.1-Update and clarification: From the RECIST committee. *European Journal of Cancer*, **2016**, 62, 132-7	7.5	607
158	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science*, **2018**, 359, 801-806	33.3	562
157	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3005-10	11.5	533
156	Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade. *Nature Immunology*, **2019**, 20, 326-336	19.1	522
155	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *Journal of Clinical Oncology*, **2016**, 34, 1510-7	2.2	509
154	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. *Nature Reviews Clinical Oncology*, **2017**, 14, 655-668	19.4	498
153	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. *Cell*, **2018** , 175, 984-997.e24	56.2	477
152	Response assessment criteria for brain metastases: proposal from the RANO group. *Lancet Oncology, The*, **2015**, 16, e270-8	21.7	472
151	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2018**, 4, 173-182	13.4	467
150	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *Journal of Clinical Oncology*, **2013**, 31, 3182-90	2.2	409
149	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2016**, 2, 1607-1616	13.4	401
148	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 4102-4109	2.2	400
147	Major response to imatinib mesylate in KIT-mutated melanoma. *Journal of Clinical Oncology*, **2008**, 26, 2046-51	2.2	373
146	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney International*, **2016**, 90, 638-47	9.9	353
145	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. *Journal of Clinical Oncology*, **2015**, 33, 2013-20	2.2	337
144	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. *Cancer Research*, **2016**, 76, 999-1008	10.1	297
143	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. *Clinical Cancer Research*, **2016**, 22, 6051-6060	12.9	292
142	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *Journal of Clinical Oncology*, **2017**, 35, 3807-3814	2.2	264

141	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. *Cancer Immunology Research*, **2017**, 5, 312-318	12.5	259
140	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 312, 1744-53	27.4	259
139	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. *Nature Genetics*, **2018**, 50, 1271-1281	36.3	249
138	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 943-955	21.7	236
137	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. *Cancer Immunology Research*, **2016**, 4, 124-35	12.5	236
136	Combination immunotherapy: a road map **2017**, 5, 16		228
135	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. *Cancer Discovery*, **2018**, 8, 196-215	24.4	228
134	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. *Science Translational Medicine*, **2018**, 10,	17.5	227
133	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. *JAMA Oncology*, **2019**, 5, 1411-1420	13.4	216
132	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. *Endocrine Reviews*, **2019**, 40, 17-65	27.2	209
131	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. *Cancer Immunology Research*, **2015**, 3, 1158-64	12.5	205
130	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. *Cancer Immunology Research*, **2017**, 5, 480-492	12.5	196
129	Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. *Science*, **2018**, 359, 1537-1542	33.3	196
128	Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nature Genetics*, **2016**, 48, 725-32	36.3	193
127	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. *Cancer Immunology Research*, **2014**, 2, 643-54	12.5	190
126	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. *Journal of Clinical Oncology*, **2018**, 36, 850-858	2.2	184
125	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. *Cancer Immunology Research*, **2015**, 3, 1185-92	12.5	168
124	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. *OncoImmunology*, **2015**, 4, e1046028	7.2	166

123	Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. *Clinical Cancer Research*, **2015**, 21, 749-55	12.9	162
122	Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. *Frontiers in Oncology*, **2015**, 5, 202	5.3	154
121	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. *Cancer Treatment Reviews*, **2014**, 40, 1056-64	14.4	146
120	CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. *Nature Clinical Practice Oncology*, **2008**, 5, 557-61		143
119	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. *Clinical Cancer Research*, **2018**, 24, 4960-4967	12.9	142
118	A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. *Nature Medicine*, **2020**, 26, 792-802	50.5	130
117	RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. *European Journal of Cancer*, **2016**, 62, 138-45	7.5	117
116	Prevalence of antibodies to 3 retroviruses in a captive colony of macaque monkeys. *International Journal of Cancer*, **1988**, 41, 601-8	7.5	115
115	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. *Cancer Immunology Research*, **2016**, 4, 289-93	12.5	112
114	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 344-351	4	107
113	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. *Cancer*, **2017**, 123, 3285-3290	6.4	106
112	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. *JAMA Oncology*, **2017**, 3, 1511-1519	13.4	101
111	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. *Cancer Immunology Research*, **2015**, 3, 1308-15	12.5	96
110	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. *JAMA Oncology*, **2016**, 2, 518-22	13.4	95
109	Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 3398-403	11.5	95
108	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. *Radiology*, **2019**, 290, 9-22	20.5	95
107	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. *Nature Communications*, **2019**, 10, 4346	17.4	89
106	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. *European Journal of Radiology*, **2015**, 84, 1259-68	4.7	89

105	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis **2018**, 6, 26		89
104	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. *JCI Insight*, **2016**, 1, e87415	9.9	89
103	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. *Clinical Cancer Research*, **2017**, 23, 3510-3519	12.9	86
102	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. *Cell*, **2020**, 182, 655-671.e22	36.2	85
101	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. *Clinical Cancer Research*, **2017**, 23, 4671-4679	12.9	84
100	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
99	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 165-174	7.1	77
98	Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. *Cancer Cell*, **2020**, 38, 500-515.e3	24.3	75
97	Tumor Mutational Burden and Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 2565-2572	12.9	71
96	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. *Cell*, **2018**, 173, 624-633.e8	56.2	71
95	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. *Cancer Immunology Research*, **2017**, 5, 1133-1140	12.5	70
94	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. *Expert Review of Anticancer Therapy*, **2015**, 15, 1389-403	3.5	70
93	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. *Clinical Cancer Research*, **2016**, 22, 3127-31	12.9	66
92	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. *Lancet Oncology, The*, **2018**, 19, e20-e32	21.7	63
91	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study **2015**, 3, 3		63
90	Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. *Nature Reviews Clinical Oncology*, **2016**, 13, 77-8	19.4	58
89	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? **2014**, 2, 17		58
88	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. *Clinical Cancer Research*, **2017**, 23, 5737-5744	12.9	55

87	Health-related quality of life results from the phase III CheckMate 067 study. *European Journal of Cancer*, **2017**, 82, 80-91	7.5	55
86	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. *Cancer Immunology Research*, **2016**, 4, 1038-1048	12.5	54
85	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. *Cancer Immunology Research*, **2015**, 3, 855-63	12.5	53
84	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. *British Journal of Cancer*, **2016**, 115, 252-60	8.7	51
83	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).. *Journal of Clinical Oncology*, **2021**, 39, 9503-9503	2.2	49
82	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. *Clinical Cancer Research*, **2019**, 25, 2174-2184	12.9	47
81	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. *Cancer*, **2018**, 124, 1111-1121	6.4	46
80	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. *Clinical Epigenetics*, **2015**, 7, 59	7.7	42
79	Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. *Cancer Immunology Research*, **2016**, 4, 12-7	12.5	42
78	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. *Cancer Immunology Research*, **2018**, 6, 1039-1045	12.5	42
77	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome **2014**, 2, 40		41
76	Sarcoid-Like Granulomatosis of the Lung Related to Immune-Checkpoint Inhibitors: Distinct Clinical and Imaging Features of a Unique Immune-Related Adverse Event. *Cancer Immunology Research*, **2018**, 6, 630-635	12.5	40
75	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6919-24	11.5	40
74	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. *Journal of Clinical Oncology*, **2021**, JCO2102229	2.2	39
73	Combinatorial cancer immunotherapy. *Advances in Immunology*, **2006**, 90, 341-68	5.6	38
72	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. *Clinical Cancer Research*, **2019**, 25, 6061-6072	12.9	33
71	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. *Cancer*, **2015**, 121, 4007-15	6.4	32
70	Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma. *Oncotarget*, **2017**, 8, 6873-6882	3.3	32

69	The biologic importance of tumor-infiltrating lymphocytes. *Journal of Cutaneous Pathology*, **2010**, 37 Suppl 1, 48-53	1.7	31
68	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. *Cancer Medicine*, **2016**, 5, 3041-3050	4.8	30
67	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. *Cancer Immunology, Immunotherapy*, **2018**, 67, 1833-1844	7.4	30
66	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. *Nature Communications*, **2019**, 10, 5157	17.4	29
65	A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. *Kidney International*, **2021**, 100, 196-205	9.9	28
64	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series **2017**, 5, 66		27
63	Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. *Genes and Diseases*, **2018**, 5, 46-48	6.6	27
62	Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. *Clinical Cancer Research*, **2008**, 14, 3896-905	12.9	27
61	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. *Cancer Immunology Research*, **2017**, 5, 1046-1055	12.5	25
60	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). *Neuro-Oncology*, **2021**, 23, 1961-1973	13	24
59	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. *Clinical Cancer Research*, **2015**, 21, 3178-86	12.9	23
58	Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. *Cancer Imaging*, **2013**, 13, 626-32	5.6	23
57	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. *European Journal of Cancer*, **2021**, 144, 182-191	7.5	23
56	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. *Cancer Immunology Research*, **2019**, 7, 1214-1220	12.5	21
55	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. *Cancer Immunology Research*, **2020**, 8, 1075-1084	12.5	21
54	Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation. *Pigment Cell and Melanoma Research*, **2016**, 29, 656-668	4.5	21
53	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**, 27, 1371-1380	12.9	18
52	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. *Melanoma Research*, **2018**, 28, 605-610	3.3	18

51	Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab. *Journal of Clinical Oncology*, **2015**, 33, e32-5	2.2	17
50	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. *Cancer Immunology Research*, **2015**, 3, 986-91	12.5	17
49	Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. *Cancer Immunology, Immunotherapy*, **2012**, 61, 655-65	7.4	17
48	Inactivation of Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. *Cancer Discovery*, **2020**, 10, 1296-1311	24.4	16
47	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. *JCO Precision Oncology*, **2017**, 1,	3.6	16
46	PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. *British Journal of Haematology*, **2018**, 180, 752-755	4.5	14
45	Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients **2016**, 4, 32		14
44	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. *Laboratory Investigation*, **2017**, 97, 207-216	5.9	13
43	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. *JCO Oncology Practice*, **2020**, 16, e933-e942	2.3	13
42	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. *Cancer Discovery*, **2021**, 11, 1524-1541	24.4	13
41	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. *Clinical Cancer Research*, **2020**, 26, 5086-5091	12.9	11
40	An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. *Clinical Cancer Research*, **2016**, 22, 5204-5210	12.9	11
39	High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples. *STAR Protocols*, **2020**, 1, 100055	1.4	11
38	Integrated molecular drivers coordinate biological and clinical states in melanoma. *Nature Genetics*, **2020**, 52, 1373-1383	36.3	11
37	Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. *Clinical Cancer Research*, **2020**, 26, 5631-5637	12.9	11
36	Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. *Cancer*, **2020**, 126, 5088-5097	6.4	11
35	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. *Blood*, **2021**, 137, 1353-1364	2.2	11
34	Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2209-2221	7.4	11

33	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. *Cancer Immunology Research*, **2021**, 9, 1202-1213	12.5	11
32	Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. *Cancer*, **2020**, 126, 3758-3767	6.4	10
31	Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. *Nature Clinical Practice Oncology*, **2008**, 5, 696-7		10
30	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. *Journal of Biological Methods*, **2019**, 6, e114	1.4	10
29	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.. *Lancet Oncology, The*, **2022**,	21.7	9
28	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. *Blood*, **2021**, 137, 3212-3217	2.2	9
27	Development of an 8-color antibody panel for functional phenotyping of human CD8+ cytotoxic T cells from peripheral blood mononuclear cells. *Cytotechnology*, **2018**, 70, 1-11	2.2	7
26	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). *Melanoma Research*, **2021**, 31, 67-75	3.3	6
25	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. *Cancer*, **2020**, 126, 5274-5282	6.4	6
24	Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients. *Npj Precision Oncology*, **2021**, 5, 62	9.8	6
23	The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. *Chinese Clinical Oncology*, **2013**, 2, 7	2.3	6
22	Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.. *Journal of Clinical Oncology*, **2014**, 32, TPS9107-TPS9107	2.2	4
21	Standardized 11-color flow cytometry panel for the functional phenotyping of human T regulatory cells. *Journal of Biological Methods*, **2020**, 7, e131	1.4	4
20	SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 axis. *Cancer Research*, **2021**,	10.1	4
19	Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. *Journal of Neuro-Oncology*, **2016**, 129, 389-393	4.8	4
18	Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. *European Journal of Cancer*, **2021**, 157, 493-510	7.5	4
17	Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma. *Cancer Immunology Research*, **2015**, 3, 59-67	12.5	3
16	Soluble PD-L1 as an early marker of progressive disease on nivolumab. **2022**, 10,		3

15	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. *Haematologica*, **2021**, 106, 651-654	6.6	3
14	Fitness Landscape of Clonal Hematopoiesis Under Selective Pressure of Immune Checkpoint Blockade. *JCO Precision Oncology*, **2020**, 4,	3.6	3
13	Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1331-1340	7.4	2
12	Hematology/Oncology Clinics of North America. Melanoma. Preface. *Hematology/Oncology Clinics of North America*, **2014**, 28, xiii-xiv	3.1	2
11	Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 **2021**, 9,		2
10	Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. *Cancer Research Communications*, **2021**, 1, 30-40		2
9	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service **2020**, 8,		2
8	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. *European Journal of Cancer*, **2021**, 157, 391-402	7.5	2
7	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. *Cancer Medicine*, **2021**, 10, 2627-2635	4.8	1
6	Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. *Journal of Immunotherapy*, **2021**, 44, 307-318	5	1
5	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). *Clinical Cancer Research*, **2021**, 27, 5038-5048	12.9	1
4	Mass cytometry staining for human bone marrow clinical samples.. *STAR Protocols*, **2022**, 3, 101163	1.4	0
3	Risk of Bias and Heterogeneity-Reply. *JAMA Oncology*, **2017**, 3, 858-859	13.4	
2	Reply to T. Olivier et al.. *Journal of Clinical Oncology*, **2022**, JCO2200209	2.2	
1	Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials.. *STAR Protocols*, **2022**, 3, 101362	1.4	